There are ten Array-invented drugs in Stage 2 clinical development presently, seven of which are partner-funded. More than another 12 months, the company expects results to become reported from the following eight clinical trials.1 million in public areas offering: Array completed an underwritten public offering of 23 million shares of its common share at a cost of $2.60 per share in February 2012. Array received net arises from the sale of the shares of $56.1 million. Hired Ron Squarer, CEO: Array employed Ron Squarer as its Chief Executive Officer in April 2012. Mr. Squarer in addition has been called to the Array Table of Directors. Mr. Squarer has comprehensive commercial, development and executive leadership experience from a 20 year career in the pharmaceutical industry.An interview with Dr Matt SilverInner hearing damage mind warnings from nerve cellsNew research from TSRI and Salk factors to reason behind debilitating nerve disease Jack Davis, Interim and Chairman CEO of Asterand commented: We highly worth our long-standing romantic relationship with Merck Serono. The studies completed by BioSeek for Merck Serono in the last three years possess demonstrated that BioMAP System may be used to reliably progress promising molecules through preclinical evaluation. Our scientists been employed by and productively with the Merck Serono closely team, and we anticipate our continuing and growing research with them..